Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)
Clinical trial NCT04233216 · COMPLETED
Trial details
- NCT number
- NCT04233216
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-18
- Primary completion
- 2022-11-21
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.